share_log

BRIEF-Shenzhen Chipscreen Biosciences Announces NMPA New Drug Approval Of Bilessglu In China

BRIEF-Shenzhen Chipscreen Biosciences Announces NMPA New Drug Approval Of Bilessglu In China

簡介-深圳芯屏生物科學公司宣佈NMPA新葯在中國獲得Bilessglu批准
reuters ·  2021/10/19 07:40

Oct 19 (Reuters) - Shenzhen Chipscreen Biosciences Co Ltd

路透10月19日電-深圳晶屏生物科學有限公司

688321.SS :

688321.SS:

* SHENZHEN CHIPSCREEN BIOSCIENCES CO LTD - ANNOUNCES NMPA NEW DRUG APPROVAL OF BILESSGLU (CHIGLITAZAR SODIUM TABLETS) FOR ( TYPE 2 DIABETES) IN CHINA

*深圳CHIPSCREEN生物科學有限公司-宣佈NMPA批准治療2型糖尿病的BILESSGLU(CHIGLITAZAR鈉片)在中國獲得新葯批准

Source text for Eikon: ID:nPn2nXW6va Further company coverage: 688321.SS

Eikon的源文本:ID:nPn2nXW6va進一步的公司報道:688321.SS

((Reuters.Briefs@thomsonreuters.com;))

(Reurs.Briefs@thomsonreurs.com;)

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論